Drug Index

Mechanism :

Tecovirimat inhibits the activity of the orthopoxvirus VP37 protein and blocks its interaction with cellular Rab9 GTPase and TIP47, preventing formation of egress-competent enveloped virions.

Indication :

  • Smallpox

Contraindications :

No contraindications.

Dosing :

13 to <25 kg:
200 mg twice daily orally for 14 days.
25 to <40 kg:
400 mg twice daily orally for 14 days.
≥40 kg:
600 mg twice daily orally for 14 days.

Adverse Effect :

Headache, tachycardia, abnormal EEG, depression, irritability, cheilosis, facial erythema, increased thirst, nausea, abdominal pain, arthralgia.

Interaction :

Midazolam: Tecovirimat may decrease the serum concentration of Midazolam.
Repaglinide: Tecovirimat may increase the serum concentration of Repaglinide.

Hepatic Dose :

No dosage adjustment is necessary
09/28/2020 07:07:08 Tecovirimat
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0